trans-3-hexenoyl raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-16. Anything still debated is marked as such rather than presented as settled.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
=== Pharmacodynamics === Compared to concentration dependent bactericidal antibiotics like aminoglycosides and fluoroquinolones, the antibacterial activity of β-lactam antibiotics are generally more time dependent. Unlike the former, when piperacillin-tazobactam concentrations exceed minimum inhibitory concentrations (MIC) of a pathogen by five folds, the exponential relationship between concentration and activity begins to level off. Otherwise, piperacillin-tazobactam bactericidal efficacy is shown to consist of a strong association with the duration of time the concentration exceeds minimum inhibitory concentrations (T>MIC). When the T>MIC in the serum equates to 60–70% of the frequency for drug administration (dosing interval), maximal activity is achieved against Gram-negative bacteria, while for Gram-positive bacteria it occurs at around 40–50%. Within a 24-hour period in one clinical study, a T>MIC surpassing 60% was found for piperacillin-susceptible bacteria including Escherichia coli, Klebsiella pneumoniae and Staphylococcus aureus in two dosing regimes (4.5 g every 8 hours and 3.375 g every 8 hours). The evidence for this was obtained through Monte Carlo experiments procured by a special program (OPTAMA), where for several different scenarios (e.g. hospital acquired infections, secondary peritonitis, skin or soft tissue infections), the probability of attaining those figures were in the ranges of 85–95% and 90–89% respectively for the two regimes.
== College career == Bill Denehy, head coach of the University of Hartford, offered Bagwell a scholarship in spite of baseball not being his primary sport. Bagwell's acceptance of Hartford's baseball scholarship was based at least in part on the lack of a professional soccer league in the United States at the time. At Hartford, Denehy switched Bagwell to third base. Over three seasons playing for Hartford, he batted .413 in 400 at bats, a school record, and, for a time, a New England collegiate record. He also was the school's career home run (31) and run batted in (126) leader when he was drafted, and a two-time Eastern College Athletic Conference player of the year. In 1987 and 1988, he played collegiate summer baseball for the Chatham A's of the Cape Cod Baseball League, and in 1988 was named the starting third baseman for the East Division in the league's annual all-star game.
== Research == JRT is being investigated as a possible treatment for schizophrenia. According to David E. Olson, his laboratory is also evaluating JRT in additional therapeutic indications, optimizing its synthesis, and developing further analogues of JRT with potentially improved properties.
In pancreatic alpha cells, proglucagon is normally cleaved predominantly by protein convertase PC2 to generate glucagon. Under conditions of metabolic stress or beta cell injury, alpha cells can increase PC1/3 expression, resulting in alternative processing of proglucagon and production of glucagon-like peptide-1 (GLP-1) and other proglucagon-derived peptides normally associated with intestinal L-cells. Alpha cells exhibit little PC2 activity and hence produce little to no GLP-1 when healthy. In contrast, (intestinal) L-cells rely on PC1/3 to exclusively produce GLP-1 and GLP-2 from proglucagon instead of glucagon. The protein convertase switch may have protective and regenerative effect on beta cells. Another possibility is that alpha cells can potentially transdifferentiate into beta cells to replace lost beta cells.
Sources: en.wikipedia.org
=== Classic genetic mutations === Drosophila genes are traditionally named after the phenotype they cause when mutated. For example, the absence of a particular gene in Drosophila will result in a mutant embryo that does not develop a heart. Scientists have thus called this gene tinman, named after the Oz character of the same name. Likewise changes in the Shavenbaby gene cause the loss of dorsal cuticular hairs in Drosophila sechellia larvae. This system of nomenclature results in a wider range of gene names than in other organisms.
===== Impact of interdiction ===== The Consolidated Counterdrug Database (CCDB) is a U.S. government dataset created in the 1990s that compiles vetted data on cocaine trafficking and seizures in the Western Hemisphere "transit zone," involving 26 U.S. agencies and 20 foreign partners. It provides a highly reliable, conservative record of cocaine movements and interdiction efforts, revealing that despite large seizures, interdiction captures only a small fraction of trafficking events and has minimal impact on U.S. cocaine prices. The CCDB challenges optimistic views of drug interdiction effectiveness and underscores the need for new policy approaches, yet remains underutilized in research despite being unclassified.
Brazil: The leaf juice is taken orally to induce vomiting and narcosis. Colombia: Fresh leaf is used as poultice over boils and infected wounds; the leaves are crushed with oil from palms and used as hair treatment to prevent baldness. Cuba: Extract of the leaf is taken orally to treat dysmenorrhea. East Africa: Dried leaves of Nicotiana tabacum and Securinega virosa are mixed into a paste and used externally to destroy worms in sores. Ecuador: Leaf juice is used for indisposition, chills and snake bites and to treat pulmonary ailments. Fiji: Fresh root is taken orally for asthma and indigestion; fresh root is applied ophthalmically as drops for bloodshot eyes and other problems; seed is taken orally for rheumatism and to treat hoarseness. Guatemala: Leaves are applied externally by adults for myiasis, headache and wounds; hot water extract of the dried leaf is applied externally for ring worms, fungal diseases of the n, wounds, ulcers, bruises, sores, mouth lesions, stomatitis and mucosa; leaf is orally taken for kidney diseases. Haiti: Decoction of dried leaf is taken orally for bronchitis and pneumonia. Hong Kong: Fresh leaves are mashed and combined with vegetable oil to create a potion that is applied to injuries for it to heal faster. This practice is also apparent in other places in China. Iran: Infusion of the dried leaf is applied externally as an insect repellent; ointments made from crushed leaves are used for baldness, dermatitis and infectious ulceration and as a pediculicide.
== Mechanism of action == The combination of lamivudine and zidovudine is composed of two nucleotide reverse transcriptase inhibitors (NRTIs). Lamivudine and zidovudine both competitively inhibit and reduce the activity of reverse transcriptase (RT) causing HIV infected cells to decrease the number of viruses in the body. Lamivudine and zidovudine act as nucleoside analogs, which are substrates for the human nucleoside kinases. The initial phosphorylation step is crucial for the drug's activity, then converted into the active 5'-triphosphate form by host kinases. The drug is then incorporated to the end of the growing chain of the viral DNA causing the chain to be terminated, where nucleotides can no longer be added to the growing viral DNA. Lamividuine and zidovudine combination therapy is believed to work synergistically together to prevent mutations in the HIV virus, which can contribute to drug resistance.
== Life and career == Aylward was born and raised in Seattle, Washington. He attended St. Joseph's Grade school and went on to Prep High School, but graduated from Garfield High School in 1965. He graduated from the Professional Actor's Training Program at the University of Washington in 1970. Beginning his acting career in Seattle, he was also one of the founders, in 1973, of Empty Space Theatre there. He worked regularly as a company member of the Seattle Repertory Theatre. He appeared in dramas by David Mamet, Arthur Miller and Tennessee Williams. Carol Flynt, co-producer of ER, first offered him an audition after seeing him in a 1996 production of Psychopathia Sexualis at the Mark Taper Forum in Los Angeles. He went on to play the recurring role of Dr. Donald Anspaugh on ER from 1996 to 2008. He also had a recurring role as former DNC chairman Barry Goodwin on The West Wing from 2005 to 2006. He also provided the voice of Dr. Arne Magnusson in the 2007 video game Half-Life 2: Episode Two. Aylward appeared in numerous television shows, including Northern Exposure, 3rd Rock from the Sun, The Practice, Law & Order and Mad Men. His film roles included Three Fugitives (1989), Teenage Mutant Ninja Turtles III (1993), Buddy (1997), Armageddon (1998), Thirteen Days (2000), and the HBO films From the Earth to the Moon (1998) and Path to War (2002). He played Father Edward Devine in the 2020 sports drama movie The Way Back. Aylward died in Seattle on May 16, 2022, at the age of 75.
Sources: en.wikipedia.org
=== Cell membrane === The urothelium is the most impermeable membrane in the mammalian body. Because of its importance in acting as an osmotic barrier between the contents of the urinary tract and the surrounding organs and tissues, transitional epithelium is relatively impermeable to water and salts. This impermeability is due to a highly keratinized cellular membrane synthesized in the Golgi apparatus. The membrane is made up of a hexagonal lattice put together in the Golgi apparatus and implanted into the surface of the cell by reverse pinocytosis, a type of exocytosis. The cells in the superficial layer of the transitional epithelium are highly differentiated, allowing for maintenance of this barrier membrane. The basal layer of the epithelium is much less differentiated; however, it does act as a replacement source for more superficial layer. While the Golgi complex is much less prominent in the cells of the basal layer, these cells are rich in cytoplasmic proteins that bundle together to form tonofibrils. These tonofibrils converge at hemidesmosomes to attach the cells at the basement membrane.
== Clinical significance == Seminal plasma contains cadaverine. Elevated levels of cadaverine have been found in the urine of some patients with defects in lysine metabolism. The odor commonly associated with bacterial vaginosis has been linked to cadaverine and putrescine.
Attempting to assert his claimed prerogatives as Her Majesty's Rhodesian Prime Minister, Smith advised the Queen by letter to appoint Dupont as Governor-General to supersede Gibbs. The letter was ignored, with Buckingham Palace characterising Smith's request as "purported advice". Whitehall maintained that Gibbs was the Queen's only legitimate representative in what it still reckoned as the colony of Southern Rhodesia–and hence, the only lawful authority in the area. Dupont nevertheless effectively replaced the Governor. The Smith administration assigned him the Governor's official residence at Government House, but no attempt was made to forcibly remove Gibbs and his entourage; the post-UDI government stated that the Officer Administering the Government would live at Governor's Lodge instead "until Government House, at present temporarily occupied by Sir Humphrey Gibbs in a private capacity, becomes available". The Speaker of the Rhodesian parliament, A. R. W. Stumbles, reconvened the Legislative Assembly on 25 November, resolving that if he did not there would be chaos. He feared that Gibbs might dramatically walk into the chamber in an attempt to stop the proceedings, but Gibbs did no such thing. The parliamentary opposition opened the meeting by asking whether the assembly was legal. Ahrn Palley, the lone white opposition MP, announced that as he saw it, "certain Honourable Members in collusion have torn up the constitution under which this House meets. The proceedings have no legal validity whatsoever".
=== Research === A major thread of Bumpus' research is determining how antiviral drugs used to treat HIV-1 are metabolized and how genetic variations in drug-processing enzymes may impact these drugs' efficacy. One antiviral commonly used to treat and prevent HIV is tenofovir (Viread). Tenofovir is a nucleotide analog reverse transcriptase inhibitor that prevents the HIV virus from replicating. Tenofovir is given in an inactive form – it has to be phosphorylated twice to become active, and this phosphorylation is carried out in two steps by separate kinases. Bumpus and her team identified which kinases do this and found that the enzymes responsible varied by cell type, so administration route (e.g. orally or topically) could affect how effectively the drug is processed. They also sequenced the genes of these kinases from different patients and found that some people have genetic variants in the kinases that may affect how effectively the drug is processed. Tenofovir can be given prophylactically, and Bumpus collaborated with researchers from around the world in a study of the use of tenofovir for HIV pre-exposure prophylaxis (PrEP) to prevent HIV infection in heterosexual men and women. Bumpus has also researched nonnucleoside reverse transcriptase inhibitors. Her lab was the first to publish the P450-catalyzed phase 1 and phase 2 metabolic pathways of two nonnucleoside reverse transcriptase inhibitors, rilpivirine and etravirine and was first to characterize the metabolism of the nonnucleoside reverse transcriptase inhibitor dapivirine.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.